Solid malignancies in individuals with down syndrome: A case presentation and literature review

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 12, Issue 11, 2014, Pages 1537-1545

  Bratman, Scott V ^a   Horst, Kathleen C ^a   Carlson, Robert W ^a,b   Kapp, Daniel S ^a  

^a STANFORD CANCER INSTITUTE   (United States)

^b National Comprehensive Cancer Network   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; DOCETAXEL; DOXORUBICIN; TAMOXIFEN; TRASTUZUMAB;

ADJUVANT THERAPY; ADULT; ARTICLE; BREAST CANCER; BREAST TUMOR; CANCER RISK; CANCER STAGING; CARDIOTOXICITY; CASE REPORT; CHROMOSOME 21; CHROMOSOME MOSAICISM; DEHYDRATION; DIARRHEA; DOWN SYNDROME; DRUG WITHDRAWAL; ENVIRONMENTAL FACTOR; EPIGENETICS; EXTERNAL BEAM RADIOTHERAPY; GENE EXPRESSION REGULATION; GENE MUTATION; GENETIC SCREENING; HEART EJECTION FRACTION; HUMAN; INTRADUCTAL CARCINOMA; MALE; MIDDLE AGED; MOSAICISM; MULTIPLE CYCLE TREATMENT; RADIATION DOSE; TRISOMY; TRISOMY 21; TUMOR SUPPRESSOR GENE; GENETICS; PATHOLOGY; RISK;

BREAST NEOPLASMS, MALE; CHROMOSOMES, HUMAN, PAIR 21; DOWN SYNDROME; HUMANS; MALE; MIDDLE AGED; RISK;

EID: 84908500980     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2014.0153     Document Type: Article

References (78)

1. Resta RG. Changing demographics of advanced maternal age (AMA) and the impact on the predicted incidence of Down syndrome in the United States: implications for prenatal screening and genetic counseling. Am J Med Genet A 2005; 133A: 31-36.
2. Hasle H, Clemmensen IH, Mikkelsen M. Risks of leukaemia and solid tumours in individuals with Down's syndrome. Lancet 2000; 355: 165-169.
3. Yang Q, Rasmussen SA, Friedman JM. Mortality associated with Down's syndrome in the USA from 1983 to 1997: a population-based study. Lancet 2002; 359: 1019-1025.
4. Glasson EJ, Sullivan SG, Hussain R, et al. The changing survival profile of people with Down's syndrome: implications for genetic counselling. Clin Genet 2002; 62: 390-393.
5. Hermon C, Alberman E, Beral V, Swerdlow AJ. Mortality and cancer incidence in persons with Down's syndrome, their parents and siblings. Ann Hum Genet 2001; 65(Pt 2): 167-176.
6. O'Brien MM, Taub JW, Chang MN, et al. Cardiomyopathy in children with Down syndrome treated for acute myeloid leukemia: a report from the Children's Oncology Group Study POG 9421. J Clin Oncol 2008; 26: 414-420.
7. Fogh S, Hirsch AE, Langmead JP, et al. Use of tamoxifen with postsurgical irradiation may improve survival in estrogen and progesterone receptorpositive male breast cancer. Clin Breast Cancer 2011; 11: 39-45.
8. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29.
9. Miao H, Verkooijen HM, Chia KS, et al. Incidence and outcome of male breast cancer: an international population-based study. J Clin Oncol 2011; 29: 4381-4386.
10. Bratman SV, Kapp DS, Horst KC. Evolving trends in the initial locoregional management of male breast cancer. Breast 2012; 21: 296-302.
11. Callari M, Cappelletti V, De Cecco L, et al. Gene expression analysis reveals a different transcriptomic landscape in female and male breast cancer. Breast Cancer Res Treat 2010; 127: 601-610.
12. Johansson I, Nilsson C, Berglund P, et al. High-resolution genomic profiling of male breast cancer reveals differences hidden behind the similarities with female breast cancer. Breast Cancer Res Treat 2010; 129: 747-760.
13. Ottini L, Rizzolo P, Zanna I, et al. BRCA1/BRCA2 mutation status and clinical-pathologic features of 108 male breast cancer cases from Tuscany: a population-based study in central Italy. Breast Cancer Res Treat 2009; 116: 577-586.
14. Ayed W, Gouas L, Penault-Llorca F, et al. Trisomy 21 and cancers [in French]. Morphologie 2012; 96: 57-66.
15. Rabin KR, Whitlock JA. Malignancy in children with trisomy 21. Oncologist 2009; 14: 164-173.
16. Zhu JL, Hasle H, Correa A, et al. Survival among people with Down syndrome: a nationwide population-based study in Denmark. Genet Med 2013; 15: 64-69.
17. Patja K, Pukkala E, Sund R, et al. Cancer incidence of persons with Down syndrome in Finland: a population-based study. Int J Cancer 2006; 118: 1769-1772.
18. Sullivan SG, Hussain R, Glasson EJ, Bittles AH. The profile and incidence of cancer in Down syndrome. J Intellect Disabil Res 2007; 51(Pt 3): 228-231.
19. Hill DA, Gridley G, Cnattingius S, et al. Mortality and cancer incidence among individuals with Down syndrome. Arch Intern Med 2003; 163: 705-711.
20. Nizetic D, Groet J. Tumorigenesis in Down's syndrome: big lessons from a small chromosome. Nat Rev Cancer 2012; 12: 721-732.
21. Boker LK, Blumstein T, Sadetzki S, et al. Incidence of leukemia and other cancers in Down syndrome subjects in Israel. Int J Cancer 2001; 93: 741-744.
22. Day SM, Strauss DJ, Shavelle RM, Reynolds RJ. Mortality and causes of death in persons with Down syndrome in California. Dev Med Child Neurol 2005; 47: 171-176.
23. Goldacre MJ, Wotton CJ, Seagroatt V, Yeates D. Cancers and immune related diseases associated with Down's syndrome: a record linkage study. Arch Dis Child 2004; 89: 1014-1017.
24. Holland WW, Doll R, Carter CO. The mortality from leukaemia and other cancers among patients with Down's syndrome (mongols) and among their parents. Br J Cancer 1962; 16: 177-186.
25. Scholl T, Stein Z, Hansen H. Leukemia and other cancers, anomalies and infections as causes of death in Down's syndrome in the United States during 1976. Dev Med Child Neurol 1982; 24: 817-829.
26. Satge D, Sasco AJ, Pujol H, Rethore MO. Breast cancer in women with trisomy 21 [in French]. Bull Acad Natl Med 2001; 185: 1239-1252; discussion 1252-1254.
27. Ehara H, Ohno K, Ito H. Benign and malignant tumors in Down syndrome: analysis of the 1514 autopsied cases in Japan. Pediatr Int 2011; 53: 72-77.
28. Satge D, Salmeron S, Homsi T, et al. Adenocarcinoma of the lung in Down syndrome: first clinical report. Tumori 2013; 99: e169-171.
29. Evenhuis HM. Medical aspects of ageing in a population with intellectual disability: III. Mobility, internal conditions and cancer. J Intellect Disabil Res 1997; 41(Pt 1): 8-18.
30. Virji-Babul N, Eichmann A, Kisly D, et al. Use of health care guidelines in patients with Down syndrome by family physicians across Canada. Paediatr Child Health 2007; 12: 179-183.
31. Satgé D, Sasco AJ. Breast screening guidelines should be adapted in Down's syndrome. BMJ. 2002; 324: 1155.
32. Tracy J, Hosken R. The importance of smoking education and preventative health strategies for people with intellectual disability. J Intellect Disabil Res 1997; 41(Pt 5): 416-421.
33. Patja K, Eero P, Iivanainen M. Cancer incidence among people with intellectual disability. J Intellect Disabil Res 2001; 45(Pt 4): 300-307.
34. Tucker MA. Melanoma epidemiology. Hematol Oncol Clin North Am 2009; 23: 383-395.
35. Satgé D, Dimoux-Dime G, Godard W, de Fréminville B. Adolescent girl with Down syndrome and lumbar cutaneous melanoma. Pediatr Dermatol 2014; 31: 108-109.
36. Clapp RW, Jacobs MM, Loechler EL. Environmental and occupational causes of cancer: new evidence 2005-2007. Rev Environ Health 2008; 23: 1-37.
37. Sakadamis A, Angelopoulou N, Matziari C, et al. Bone mass, gonadal function and biochemical assessment in young men with trisomy 21. Eur J Obstet Gynecol Reprod Biol 2002; 100: 208-212.
38. Arnell H, Gustafsson J, Ivarsson SA, Anneren G. Growth and pubertal development in Down syndrome. Acta Paediatr 1996; 85: 1102-1106.
39. Hsiang YH, Berkovitz GD, Bland GL, et al. Gonadal function in patients with Down syndrome. Am J Med Genet 1987; 27: 449-458.
40. Canfield KN, Spector LG, Robison LL, et al. Childhood and maternal infections and risk of acute leukaemia in children with Down syndrome: a report from the Children's Oncology Group. Br J Cancer 2004; 91: 1866-1872.
41. Nunez-Enriquez JC, Fajardo-Gutierrez A, Buchan-Duran EP, et al. Allergy and acute leukaemia in children with Down syndrome: a population study. Report from the Mexican inter-institutional group for the identification of the causes of childhood leukaemia. Br J Cancer 2013; 108: 2334-2338.
42. Flores-Lujano J, Perez-Saldivar ML, Fuentes-Panana EM, et al. Breastfeeding and early infection in the aetiology of childhood leukaemia in Down syndrome. Br J Cancer 2009; 101(5): 860-864.
43. Blair CK, Roesler M, Xie Y, et al. Vitamin supplement use among children with Down's syndrome and risk of leukaemia: a Children's Oncology Group (COG) study. Paediatr Perinat Epidemiol 2008; 22: 288-295.
44. Ross JA, Blair CK, Olshan AF, et al. Periconceptional vitamin use and leukemia risk in children with Down syndrome: a Children's Oncology Group study. Cancer 2005; 104: 405-410.
45. Biesecker LG, Spinner NB. A genomic view of mosaicism and human disease. Nat Rev Genet 2013; 14: 307-320.
46. Modi D, Berde P, Bhartiya D. Down syndrome: a study of chromosomal mosaicism. Reprod Biomed Online 2003; 6: 499-503.
47. Fishler K, Koch R, Donnell GN. Comparison of mental development in individuals with mosaic and trisomy 21 Down's syndrome. Pediatrics 1976; 58: 744-748.
48. Papavassiliou P, York TP, Gursoy N, et al. The phenotype of persons having mosaicism for trisomy 21/Down syndrome reflects the percentage of trisomic cells present in different tissues. Am J Med Genet A 2009; 149A: 573-583.
49. Sussan TE, Yang A, Li F, et al. Trisomy represses Apc(Min)-mediated tumours in mouse models of Down's syndrome. Nature 2008; 451: 73-75.
50. Schvartzman JM, Sotillo R, Benezra R. Mitotic chromosomal instability and cancer: mouse modelling of the human disease. Nat Rev Cancer 2010; 10: 102-115.
51. Ganmore I, Smooha G, Izraeli S. Constitutional aneuploidy and cancer predisposition. Hum Mol Genet 2009; 18(R1): R84-93.
52. Hattori M, Fujiyama A, Taylor TD, et al. The DNA sequence of human chromosome 21. Nature 2000; 405: 311-319.
53. Bacher U, Kern W, Schnittger S, et al. Further correlations of morphology according to FAB and WHO classification to cytogenetics in de novo acute myeloid leukemia: a study on 2, 235 patients. Ann Hematol 2005; 84: 785-791.
54. Berger R. Acute lymphoblastic leukemia and chromosome 21. Cancer Genet Cytogenet 1997; 94: 8-12.
55. Heerema NA, Raimondi SC, Anderson JR, et al. Specific extra chromosomes occur in a modal number dependent pattern in pediatric acute lymphoblastic leukemia. Genes Chromosomes Cancer 2007; 46: 684-693.
56. Malinge S, Izraeli S, Crispino JD. Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndrome. Blood 2009; 113: 2619-2628.
57. Kirsammer G, Jilani S, Liu H, et al. Highly penetrant myeloproliferative disease in the Ts65Dn mouse model of Down syndrome. Blood 2008; 111: 767-775.
58. Carmichael CL, Majewski IJ, Alexander WS, et al. Hematopoietic defects in the Ts1Cje mouse model of Down syndrome. Blood 2009; 113: 1929-1937.
59. Alford KA, Slender A, Vanes L, et al. Perturbed hematopoiesis in the Tc1 mouse model of Down syndrome. Blood 2010; 115: 2928-2937.
60. Malinge S, Bliss-Moreau M, Kirsammer G, et al. Increased dosage of the chromosome 21 ortholog Dyrk1a promotes megakaryoblastic leukemia in a murine model of Down syndrome. J Clin Invest 2012; 122: 948-962.
61. Arron JR, Winslow MM, Polleri A, et al. NFAT dysregulation by increased dosage of DSCR1 and DYRK1A on chromosome 21. Nature 2006; 441: 595-600.
62. Minami T, Horiuchi K, Miura M, et al. Vascular endothelial growth factor- and thrombin-induced termination factor, Down syndrome critical region-1, attenuates endothelial cell proliferation and angiogenesis. J Biol Chem 2004; 279: 50537-50554.
63. Baek KH, Zaslavsky A, Lynch RC, et al. Down's syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1. Nature 2009; 459: 1126-1130.
64. O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88: 277-285.
65. Reynolds LE, Watson AR, Baker M, et al. Tumour angiogenesis is reduced in the Tc1 mouse model of Down's syndrome. Nature 2010; 465: 813-817.
66. Zorick TS, Mustacchi Z, Bando SY, et al. High serum endostatin levels in Down syndrome: implications for improved treatment and prevention of solid tumours. Eur J Hum Genet 2001; 9: 811-814.
67. Kwak HI, Gustafson T, Metz RP, et al. Inhibition of breast cancer growth and invasion by single-minded 2s. Carcinogenesis 2007; 28: 259-266.
68. Ge Y, LaFiura KM, Dombkowski AA, et al. The role of the proto-oncogene ETS2 in acute megakaryocytic leukemia biology and therapy. Leukemia 2008; 22: 521-529.
69. Pritchard MA, Kola I. The "gene dosage effect" hypothesis versus the "amplified developmental instability" hypothesis in Down syndrome. J Neural Transm Suppl 1999; 57: 293-303.
70. Jiang J, Jing Y, Cost GJ, et al. Translating dosage compensation to trisomy 21. Nature 2013; 500: 296-300.
71. Letourneau A, Santoni FA, Bonilla X, et al. Domains of genome-wide gene expression dysregulation in Down's syndrome. Nature 2014; 508: 345-350.
72. Lane AA, Chapuy B, Lin CY, et al. Triplication of a 21q22 region contributes to B cell transformation through HMGN1 overexpression and loss of histone H3 Lys27 trimethylation. Nat Genet 2014; 46: 618-623.
73. Adorno M, Sikandar S, Mitra SS, et al. Usp16 contributes to somatic stemcell defects in Down's syndrome. Nature 2013; 501: 380-384.
74. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001; 414: 105-111.
75. Al-Hajj M, Wicha MS, Benito-Hernandez A, et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003; 100: 3983-3988.
76. Nguyen LV, Vanner R, Dirks P, Eaves CJ. Cancer stem cells: an evolving concept. Nat Rev Cancer 2012; 12: 133-143.
77. Joo HY, Zhai L, Yang C, et al. Regulation of cell cycle progression and gene expression by H2A deubiquitination. Nature 2007; 449: 1068-1072.
78. Tabares-Seisdedos R, Dumont N, Baudot A, et al. No paradox, no progress: inverse cancer comorbidity in people with other complex diseases. Lancet Oncol 2011; 12: 604-608.